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V I R O L O G Y
Liver-expressed Cd302 and Cr1l limit hepatitis C virus 
cross-species transmission to mice
Richard J. P. Brown1,2*, Birthe Tegtmeyer2, Julie Sheldon2, Tanvi Khera2,3, Anggakusuma2,4, 
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Gisa Gerold8,9, Eike Steinmann2,5, Qinggong Yuan10,11, Michael Ott10,11,  
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Alexander W. Tarr21,22, C. Patrick McClure21,22, Glenn Randall23, Yasmine Baktash24, 
Alexander Ploss25, Viet Loan Dao Thi26,27, Eleftherios Michailidis27, Mohsan Saeed26,28, 
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Charles M. Rice26, Thomas Pietschmann2,13,15*
Hepatitis C virus (HCV) has no animal reservoir, infecting only humans. To investigate species barrier determinants 
limiting infection of rodents, murine liver complementary DNA library screening was performed, identifying 
transmembrane proteins Cd302 and Cr1l as potent restrictors of HCV propagation. Combined ectopic expression 
in human hepatoma cells impeded HCV uptake and cooperatively mediated transcriptional dysregulation of a 
noncanonical program of immunity genes. Murine hepatocyte expression of both factors was constitutive and not 
interferon inducible, while differences in liver expression and the ability to restrict HCV were observed between 
the murine orthologs and their human counterparts. Genetic ablation of endogenous Cd302 expression in human 
HCV entry factor transgenic mice increased hepatocyte permissiveness for an adapted HCV strain and dysregulated 
expression of metabolic process and host defense genes. These findings highlight human-mouse differences in 
liver-intrinsic antiviral immunity and facilitate the development of next-generation murine models for preclinical 
testing of HCV vaccine candidates.
INTRODUCTION
Hepatitis C virus (HCV) chronically infects 71 million people world-
wide, resulting in 400,000 deaths per year (1). Despite major advances 
in antiviral treatment, no vaccine for HCV is available, and with 
ca. 1.75 million new infections in 2015, virus transmission rates remain 
high (2). HCV can establish chronic infections in the human liver, 
causing progressive liver damage and leading to severe complications 
including cirrhosis and hepatocellular carcinoma. In general, viruses 
are usually well adapted to their host, and cross-species transmissions 
can be limited by host factor incompatibilities and restriction fac-
tors (3). Tropism and pathogenesis depend on exploitation of host 
factors supporting infection and evasion of cellular antiviral mecha-
nisms (4, 5). HCV naturally infects only humans, preventing studies 
of progressive immunopathogenesis or preclinical testing of novel 
therapeutics in an immunocompetent animal model. Recently, in 
attempts to address this problem, related viruses infecting diverse 
species have been repurposed as infection models for hepaciviruses 
(6–9) in their natural hosts. However, these viruses are substantially 
divergent from their human-infecting counterpart, HCV, limiting 
their usefulness for clinical infection research. Previous work only 
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partially defined the species barrier determinants that restrict the 
HCV host range to humans. Ablation of innate immune responses, 
coupled with ectopic supplementation of human entry factors CD81 
and occludin (OCLN), increases HCV permissiveness of murine 
hepatocytes in vitro (10) and in vivo (11, 12). Despite this, viral rep-
lication remained low. These studies point to the existence of addi-
tional unknown barriers to increased HCV susceptibility in the 
murine liver. This knowledge gap has impeded development of 
murine models for this important human pathogen, causing a sub-
stantial disease burden globally.
RESULTS
Murine Cd302 and Cr1l are pan-genotypic restrictors of  
HCV infection
This study aimed to identify restriction factors suppressing HCV 
replication in the murine liver. To this end, we screened a cDNA 
library generated from the liver of an interferon (IFN)–treated mouse. 
The library was packaged in lentiviral/VSV-glycoprotein–enveloped 
pseudoparticles and transduced into n4mBid cells (S0), followed by 
two rounds of selection (S2) with cell culture–derived HCV (HCVcc, 
strain Jc1) (Fig. 1A). The human n4mBid cell line is a genetically 
modified Huh-7.5 derivative with an HCV-triggered cell death pheno-
type: n4mBid cells are highly permissive for HCV but undergo 
apoptosis upon HCV replication due to NS3-4A protease-mediated 
cleavage of a modified Bid protein (13). Two rounds of selection 
with HCV were performed, and surviving cells were expanded after 
each round of selection. RNA sequencing (RNA-seq) profiling of 
cell population S0, the initial n4mBid cell population after delivery 
of the cDNA library, and cell population S2, the population of cells 
after two consecutive challenges with HCV, revealed 1 to 2% of 
reads mapped to the mouse transcriptome (fig. S1), representing 
the integrated cDNA library. The majority of these integrated genes 
were protein coding loci (fig. S1). Infection with Renilla luciferase 
(R-luc) reporter HCV (genotype 2a, strain Jc1) revealed that S2 cells 
were 200-fold less permissive for HCV when compared to S0, while 
susceptibility for human coronavirus R-luc infection (strain 229E) 
remained unaffected (Fig. 1B). To identify the determinants of this 
phenotype, comparative analyses of human cellular and lentivirally 
transduced mouse transcriptomes from S0 and S2 cell populations 
were performed. No depletion of known human HCV dependency 
factors was apparent (fig. S1), while enrichment of mRNAs repre-
senting a subset of integrated murine genes was observed. Ten mu-
rine genes met our inclusion criteria for enrichment [S2 reads per 
kilobase per million bases mapped (RPKM) value >100, −log10 P > 5] 
(Fig. 1C, left) and were individually investigated via lentiviral over-
expression and subsequent infection with firefly luciferase (F-luc) 
reporter HCV (strain Jc1) (Fig. 1C, right). Subsequently, we focused on 
the two most potent HCV restrictors: murine Cd302 (also known as 
Dcl-1 and Clec13a) and Cr1l [complement component (3b/4b) re-
ceptor 1–like; also known as Crry]. Both were strongly enriched during 
HCV selection and abundantly expressed in the S2 population—in 
addition, their ectopic expression reduced HCV infection by greater 
than 50%.
Infection of Huh-7.5 cells ectopically expressing either mCr1l or 
mCd302 with R-luc HCV (strain Jc1) revealed a 10- or 50-fold 
reduction in intracellular relative light units (RLU) accumulation 
over a 4- to 96-hour time course, respectively, when compared to 
the control cell line (Fig. 1D). The level of restriction conferred by 
either mCd302 or mCr1l was considerably greater than that observed 
for human NOS2, a described anti-HCV factor (14). Combined 
mCd302/mCr1l expression enhanced the antiviral effect, suggesting 
that these proteins may act in concert, with RLU counts 200-fold 
reduced compared to the control cell line (Fig. 1D). Next, we per-
formed infections of murine restriction factor–expressing cell lines 
with a panel of R-luc reporter HCV chimeras, encoding core-NS2 
from genotypes 1 to 7 and NS3-NS5B from strain JFH-1. These 
strains encompass the genetic and antigenic diversity apparent in 
the structural proteins from globally sampled HCV isolates. We ob-
served varied but potent restriction of infection by all HCV geno-
types (Fig. 1E). In general, in agreement with genotype 2a infections, 
combined mCd302/mCr1l restriction was more potent than either 
factor alone. Infection of Huh-7.5 cells overexpressing mCd302 and 
mCr1l (individually or in combination) with nonreporter HCV 
(strain Jc1) revealed an identical restriction phenotype to that ob-
served with reporter HCV (Fig. 1F): A marked reduction of both 
intracellular viral RNA (vRNA, top) or secreted virions (bottom) was 
apparent at 72 hours post-infection (hpi) when compared to con-
trol cells. To confirm that mCd302 and mCr1l also restrict patient- 
derived primary isolates, we ectopically expressed human SEC14L2 
in Huh-7.5 cells, which was previously shown to facilitate the prop-
agation of primary HCV isolates in tissue culture (15). Huh-7.5–
SEC14L2 cells supported infection with sera of patients infected 
with genetically diverse HCV subtypes (1a, 1b, and 3a), which could 
be suppressed with daclatasvir—an inhibitor of the HCV NS5A 
phosphoprotein. Combining ectopic SEC14L2 expression with either 
mCd302 or mCr1l, we observed that both murine factors restrict 
infection of Huh-7.5 cells with HCV patient isolates (Fig. 1G).
To investigate the breadth of mCd302 and mCr1l antiviral re-
striction, we conducted infection assays using a divergent panel of 
viruses. The related flaviviruses dengue virus (DENV), West Nile 
virus (WNV), and yellow fever virus (YFV), which are all transmitted 
by mosquito vectors, were not impaired by mCd302 and mCr1l 
overexpression. Similarly, infection with human respiratory syncy-
tial virus (hRSV) and a zoonotic strain of the hepatotropic hepatitis 
E virus (HEV) was not significantly impeded (fig. S2), although a 
modest effect on HEV replication could be observed. Together, 
these data indicate that murine Cd302 and Cr1l mediate a strong 
and cooperative antiviral effect against HCV.
Cd302 and Cr1l coexpression inhibits HCV cell entry
Cellular localization of overexpressed mCd302 and mCr1l in Huh-
7.5 cells was investigated by flow cytometry and immunofluorescence 
staining, revealing distribution of both proteins throughout the 
cytosol and concentration of expression at the plasma membrane 
(Fig. 2A). To investigate whether HCV infection was impeded at an 
early stage of the viral life cycle, we infected cells with lentiviral 
pseudoparticles decorated with HCV envelope proteins (HCVpps) 
from different strains (Con1 and UKN2B2.8) and compared them 
to HCVcc infections (Fig. 2B). These data revealed an entry-specific 
effect only for mCd302 but not for mCr1l alone. However, entry- 
specific restriction of mCd302 was further enhanced by coexpression 
with mCr1l, indicating that both factors act cooperatively to impede 
HCVpp entry. The level of restriction on HCVpp entry was 10- to 
20-fold less than that observed for HCVcc infection. This could be 
due to differences between authentic virions and HCVpps includ-
ing differences in envelope glycoprotein membrane incorporation, 
envelope lipid composition, N-linked glycosylation, lipoprotein 
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Fig. 1. Identification of murine restriction factors. (A) Library screening protocol. (B) Library-transduced cell line susceptibility to infection. Reporter HCV and 
human CoV-229E infections were conducted in parental Huh-7.5 cells, n4mBid S0 cells, and n4mBid S2 cells. Curves represent fold RLU increase over 4 hours post-infection (hpi), 
and values presented are means of n = 4 experiments ± the SEM. RLU, relative light units. (C) Identification of murine restriction factor candidates. Left: Genome-wide com-
parison of S0 and S2 integrated murine library (n = 2). Circles represent individual genes and are proportional to RPKM fold enrichment from S0 to S2, with associated P values 
plotted on the y axis. The dashed line represents the significance threshold. Right: HCV F-luc infection of Huh-7.5 cells ectopically expressing the indicated factors. Data 
presented were normalized to EMTPY values (100%) and represent the means of n ≥ 5 experiments + SEM. (D) Restriction of reporter HCV infection. HCV R-luc infection of 
Huh-7.5 cells ectopically expressing the indicated genes. Curves represent fold RLU increase over 4 hpi, and values presented are means of n ≥ 4 experiments ± SEM. 
(E) Restriction of all HCV genotypes. Indicated cell lines were infected with chimeric R-luc reporter viruses with color coding identical to (D). Data represent mean fold RLU increase 
over uninfected cells from n = 3 experiments + SEM. ns, not significant. (F) Restriction of nonreporter HCV. Infection of the indicated cells with WT HCV (strain Jc1) results in reduced 
vRNA and virion production. Mean data + SEM are plotted for n = 5 experiments. MOI: multiplicity of infection; TCID50, mean tissue culture infectious dose; nd, none detected; 
LOQ, limit of quantification. (G) Restriction of patient-derived HCV. Cell lines ectopically expressing the indicated factors, with and without SEC14L2 coexpression, were infected 
with primary isolates of the indicated subtypes. Bars represent means of n = 2 technical replicates + SEM. DVR, daclatasvir. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.
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Fig. 2. Murine Cd302 and Cr1l impede HCV entry. (A) Cellular localization of murine Cd302 and mCr1l. Left: Surface expression of Cd302 or Cr1l determined by flow 
cytometry. 2o, secondary only; Iso, isotype control; Neg, unstained. Right: Immunofluorescence staining of the corresponding cell lines. (B) Cd302 and Cr1l impede entry 
of HCV pseudoparticles. Permissiveness of indicated cell lines to infection with HCVcc or HCVpp. Data are normalized to infection rates for EMPTY Huh-7.5 cells (100%) 
and represent means of n = 3 experiments + SEM. (C) Impaired HCV entry kinetics in polarized organoids. Top: Experimental procedure. Minutes post temperature shift 
(mpts). Bottom: Cd302 and Cr1l impede HCV translocation to the tight junction. Percentage of DiD-HCV located at tight junctions at the indicated time points. Data are 
normalized to total HCV particles per cell line at each individual time point (100%) and represent means of n = 3 experiments ± SD. (D) HCV directly binds Cd302 and Cr1l. 
Left: Binding of HCVcc to surface-expressed mCd302 and mCr1l. Data represent means + SEM from n = 5 experiments. Right: FACS analysis of nonpermeabilized CHO-745 
cells overexpressing the indicated factors. Untransfected CHO-745 cells are highlighted in black, while unstained cells are shown in gray. (E) The C-type lectin domain and 
cytoplasmic tail of mCd302 combine to mediate HCV restriction. Protein cartoons denote domains of WT mCd302 with the position of engineered deletion or point 
mutants highlighted. Data represent the RLU means + SEM of n = 5 experiments normalized to infection rates in EMPTY cells. Mutated/deleted residues in the CPT are 
highlighted below. (F) The ectodomain of mCr1l mediates HCV restriction. Protein cartoon to the left denotes the relative functional domains of mCr1l. Data represent 
RLU means + SEM at 72 hpi of n = 5 experiments normalized to infection rates in EMPTY cells. ****P < 0.0001, ***P < 0.001, **P < 0.01, and *P < 0.05.
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association, or the absence of secondary rounds of infection for 
HCVpps. Alternatively, the observed differences between HCVcc 
and HCVpp restriction may be due to additional targeting of post- 
entry stages, which are not recapitulated in the pseudoparticle 
infection assay.
To probe whether mCd302 and mCr1l impede HCV cell surface 
trafficking in polarized cells, we used a single-particle tracking 
assay. In this assay, Matrigel-polarized Huh-7.5 hepatoma cell or-
ganoids, which recapitulate the polarization of hepatocytes in vivo, 
were inoculated with purified, DiD-labeled HCV particles (16). 
Organoids transduced with an EMPTY vector, mCd302, or mCr1l/ 
mCd302 were inoculated with DiD-HCV at 4°C; unbound particles 
were washed away; and cells were shifted to 37°C to enable real-time 
visualization of bound particle trafficking to the tight junction 
(Fig. 2C, top). Organoids were fixed at multiple time points (min-
utes post temperature shift: mpts) and stained for ZO-1, a tight 
junction marker protein, DiD-HCV, and organoid nuclei. EMPTY 
vector cells showed a maximum colocalization of HCV with ZO-1 
at 90 mpts consistent with previous data (16). However, organoids 
expressing mCd302 or mCr1l/mCd302 displayed significantly lower 
colocalization at 0 and 90 mpts (Fig. 2C, bottom). These data 
suggest a defect in trafficking to the tight junction, a crucial step 
in the HCV uptake process. Furthermore, while colocalization with 
control organoids drops off at 360 mpts, indicating that particles 
have internalized, DiD-HCV particles in mCr1l/mCd302 organoids 
maintained colocalization with ZO-1, suggesting a possible inter-
nalization defect. Together, these data imply that mCd302 and mCr1l 
mediate their anti-HCV effect, in part, by disrupting steps of the 
complex entry cascade.
To investigate whether surface-expressed mCd302 and mCr1l 
proteins bind directly to HCV particles, we incubated HCVcc parti-
cles with either untransfected CHO-745 cells or CHO-745 cells 
transfected with mCd302, mCr1l, or mCr1l/mCd302 plasmids. CHO-
745 cells were used for the HCV attachment assay, because they lack 
endogenous expression of canonical HCV entry factors and are 
deficient in synthesis of proteoglycans due to a defect in xylosyl-
transferase activity, thus reducing nonspecific background binding. 
We used CHO-745 cells expressing the human HCV entry receptor 
SCARB1, which is known to bind virions directly, as a control (17–19). 
HCV was incubated with cells, followed by washing, RNA extraction, 
and quantification cell-bound vRNA by reverse transcription quanti-
tative polymerase chain reaction (RT-qPCR) (Fig. 2D, left). Similar 
to cells expressing SCARB1, murine restriction factor expressing–
cells exhibited ~3-fold more surface-bound HCV RNA when com-
pared to untransfected CHO-745 cells, suggesting that both mCd302 
and mCr1l can directly bind HCV, comparable to the levels seen for 
the HCV entry factor SCARB1. Surface localization of ectopically 
expressed factors was confirmed by flow cytometry. While cell sur-
face localization of murine factors in CHO-745 cells was lower than 
that observed for human SCARB2, surface detection was apparent 
for both Cd302 and Cr1l (Fig. 2D, right).
Cd302 restriction is mediated by the C-type lectin domain 
and critical residues in the cytoplasmic tail
The murine Cd302 gene encodes a 228–amino acid type I trans-
membrane protein containing a SP (SP; 20 amino acids), a CTLD 
(CTLD; 132 amino acids), a spacer region (S; 13 amino acids), a TM 
(TM; 24 amino acids), and a CPT (CPT; 39 amino acids) (20, 21). 
To determine the mCd302 domain(s) important for the observed 
anti-HCV restriction, we initially generated two mCd302 domain 
deletion constructs: CTLD and CPT. While deletion of the 
CTLD partially ablated the restriction phenotype, truncation of 
the CPT completely ablated the inhibition of HCV infection 
(Fig. 2E, left). Expression and cell surface localization of the CPT 
mutant protein were largely unaffected (fig. S3). In contrast, as the 
-mCd302 antibody binds to the CTLD, the ability to detect this 
mutant protein was lost (fig. S3). Putative functional residues/
motifs in the mCd302 CPT include a single cysteine residue (C213), 
which could serve as a putative palmitoylation site; two tyrosine resi-
dues (Y209 and Y223), which could be phosphorylated and involved 
in downstream signaling; and an EEDE acidic patch (219 to 222), 
which could serve as an internalization motif. Mutation/deletion of 
any of these critical residues completely destroyed the HCV restric-
tion phenotype of Cd302 (Fig. 2E, right), while protein expression 
was unaffected (fig. S3). Cell surface expression of Cd302 CPT 
mutants was reduced compared to Cd302 wild type (WT), although 
still detectable (fig. S3).
The murine Cr1l gene encodes a 440–amino acid transmembrane 
protein containing an SP (40 amino acids), an ED (ED; 310 amino 
acids), a TM (36 amino acids), and a CPT (54 amino acids). In con-
trast to mCd302, CPT of mCr1l had no effect on the capacity to re-
strict HCV infection, while deletion of the transmembrane domain 
and CPT together (TM + CPT) disrupted plasma membrane in-
corporation and ablated HCV restriction (Fig. 2F). Together, these 
data identified the domains in each protein critical for the anti-HCV 
phenotype. Both the C-type lectin domain and the cytoplasmic tail 
are required for mCd302 to restrict HCV, with the cytoplasmic tail 
integral for restriction. In contrast, the ectodomain and membrane 
incorporation are required for mCr1l restriction.
Cd302/Cr1l restriction correlates with induction of a unique 
transcriptional program
Next, we explored whether mCr1l/mCd302 restriction is dependent 
on IFN signaling. As both type I and type III IFNs signal via the 
Janus kinase–signal transducer and activator of transcription 1 
(JAK/STAT1) signaling cascade, we treated ectopically expressing 
cell lines with the JAK/STAT inhibitor ruxolitinib, IFN (IFN, sub-
type 2a), or a combination of both, followed by infection with HCV. 
JAK/STAT inhibition alone could not ablate HCV restriction in 
cells overexpressing mCd302/mCr1l, although the antiviral effect of 
IFN could be ablated and the infection phenotype could be rescued 
(Fig. 3A). These data indicate that murine mCd302/mCr1l restric-
tion occurs independently of the JAK/STAT pathway.
To further investigate the mechanism of restriction, we used 
transcriptional profiling of Huh-7.5 cell lines ectopically expressing 
murine restriction factors (mCd302, mCr1l, and mCd302/mCr1l) 
and compared dysregulated genes signatures to control cell lines 
(EMPTY and mCd302CPT), which are highly permissive for HCV 
infection. Levels of critical HCV entry factors SCARBI, CD81, 
OCLN, and CLDN1 mRNA and cell surface protein expression were 
comparable in permissive and restricting cell lines. Likewise, mRNA 
levels of replication or assembly cofactor mRNAs PI4KA, PPIA, and 
APOE were also comparable (fig. S4). Analysis of differentially 
expressed genes (DEGs) in each cell line (when compared to the 
EMPTY cell line that is highly permissive for HCV infection) showed 
that HCV-permissive mCd302CPT cell transcriptomes were com-
parable to EMPTY cells, with relatively few DEGs detected (Fig. 3B). 
Of note, we observed increasing numbers of DEGs in mCr1l, mCd302, 
Brown et al., Sci. Adv. 2020; 6 : eabd3233     4 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
6 of 18
and mCr1l/mCd302 cells, respectively, suggesting an additive or 
cooperative effect of overexpressing both factors in parallel, with ~200 
DEGs apparent in mCr1l/mCd302 cells (Fig. 3B). To investigate 
whether these two proteins physically interact, we performed immuno-
precipitations. Coimmunoprecipitation of mCr1l with hemagglutinin 
(HA)–tagged mCd302 confirmed the mCd302-mCr1l interaction, 
indicating that both factors might bind each other and act coopera-
tively to mediate their combined potent anti-HCV phenotype (Fig. 3C). 
Stringent analyses of mCr1l- and mCd302-specific DEGs [false dis-
covery rate (FDR) P <0.05, only transcripts with RPKM >1 included] 
revealed a program of dysregulated genes in mCd302 cells, which 
was further enhanced by coexpression with mCr1l (Fig. 3D). Cells 
ectopically expressing mCd302CPT exhibited minimal DEGs, sug-
gesting that mCr1l/mCd302-dependent transcriptional changes are 
dependent on the CPT of mCd302. In many cases, ectopic expression 
of mCr1l and mCd302 individually up-regulated the same target gene 
and concomitant expression of both mCr1l/mCd302 that further 
boosted expression of these targets (e.g., ACY3, ALPI, C19orf33, 
and TFF1), underpinning cooperativity between mCr1l and mCd302 
in transcriptional regulation of cellular genes. The majority of mCr1l/ 
mCd302-specific DEGs (88 of 122) represented IFN-regulated genes 
(IRGs) (22). These data indicate that overexpression of mCr1l/ mCd302 
results in the dysregulation of a specific subset of antiviral genes, 
which likely contributes an intrinsic anti-HCV phenotype.
Cd302 and Cr1l are constitutively expressed in murine 
hepatocytes and not induced by IFN
We next investigated whether murine hepatocytes express these 
identified restriction factors. Transcriptional profiling of total mouse 
livers and plated primary mouse hepatocytes (PMHs) from multiple 
standard laboratory strains revealed abundant expression of mCd302 
and mCr1l mRNA transcripts, comparable to well-characterized 
hepatocyte-specific transcripts (Fig. 4A). In contrast, brain- or 
lung-specific mRNAs were either barely detectable or completely 
absent. We observed constitutive expression of mCd302 and mCr1l 































Fig. 3. Murine Cd302 and Cr1l interact and ectopic expression modulates the intrinsic Huh-7.5 transcriptome. (A) JAK/STAT inhibition does not ablate HCV restric-
tion. Pretreatment of the indicated cell lines with JAK/STAT inhibitor (ruxolitinib), IFN (subtype 2a), or ruxolitinib and IFN in combination, followed by infection and 
readministration at 4 hpi. Data represent RLU means + SEM at 72 hpi of n = 3 experiments normalized to infection rates in EMPTY cells treated with a DMSO vehicle control. 
(B) Ectopic mCd302 and mCr1l expression modulates the Huh-7.5 transcriptome. Data represent the number of differentially expressed genes (DEGs) (FDR P < 0.05) in each 
cell line when compared to EMPTY cells and are derived from RNA-seq of n = 3 replicates from nonidentical passages per cell line. *IRGs determined using Interferome 
v2.0 (22). (C) mCd302 and mCr1l proteins interact. Protein: Protein interaction of double HA-tagged mCd302 (2HACd302) and WT mCr1l was confirmed by immuno-
precipitation of nuclear depleted cell lysates from double overexpressing cells via incubation with anti-HA resin followed by Western blotting detection with -Cd302 and 
-Cr1l antibodies. (D) Ectopic mCd302 and mCr1l expression dysregulates a noncanonical gene program. Heatmap visualization of DEGs in mCd302/mCr1l cells described 
in (B) (FDR P < 0.05, final RPKM >1) with cellular mRNA expression of the indicated genes (RPKM) presented as fold change relative to EMPTY cells. Black diamonds asso-
ciated with gene names represent IRGs. The proportion of IRGs is presented as a pie chart, with number of genes in each category inset. Black, IRG; and gray, non-IRG.
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confocal microscopy, with distribution throughout the cytosol and 
a notable fraction of mCr1l localized to a perinuclear compartment 
(Fig. 4B). In situ staining of formalin fixed paraffin embedded (FFPE) 
mouse liver slices confirmed mCr1l membranous localization in 
hepatocytes (Fig. 4C) and, in agreement with this observation, flow 
cytometry of nonpermeabilized mouse hepatocytes revealed a sub-
fraction of both proteins localized to the cell surface (Fig. 4D). 
Together, these data confirm constitutive expression of mCd302 and 
mCr1l mRNAs and encoded protein in murine livers and hepato-
cytes, the analogous target cells for HCV infection in humans.
Antiviral responses to RNA viruses in hepatocytes are mediated 
by at least two distinct, non-overlapping sensing pathways: retinoic 
Fig. 4. mCd302 and mCr1l are constitutively expressed in murine hepatocytes. (A) High intrinsic expression of mCd302 and mCr1l mRNA in murine livers and hepato-
cytes. Intrinsic mRNA expression of selected genes present in total liver (TL) and plated primary mouse hepatocytes (PMHs) from the indicated mouse strains. Cells with 
X represent genes with no detectable expression (RPKM = 0). (B) Cellular localization of mCd302 and mCr1l proteins in murine hepatocytes. Immunofluorescence analysis 
of -mCd302 or -mCr1l antibody staining on plated PMHs determined by confocal microscopy with secondary only antibody staining controls. Insets magnify the peri-
nuclear concentration of both proteins. (C) In situ staining of mCr1l in mouse liver slices. Immunohistochemical staining of mCr1l in murine liver slices versus unstained 
and pelleted Huh-7.5 [mCr1l] controls. (D) Cell surface localization of mCd302 and mCr1l on mouse hepatocytes. FACS staining of nonpermeabilized mouse hepatocytes 
with -mCd302 or -mCr1l antibodies, compared to secondary antibody only staining and unstained controls. (E) mCd302 and mCr1l mRNA are not inducible. Heatmaps 
showing fold change (FC) in mRNA expression of candidate genes in PMHs derived from the indicated mouse strains. PMHs were either untreated or treated with IFN2a 
or PolyI:C. Fold regulation was compared to Ifn or Isg15 induction. Four hours post treatment (4 hpt). (F) Species-specific differences in Cd302 evolution. Left: Phylogenetic 
tree depicting the evolutionary relationships of placental mammal Cd302 sequences with significant bootstrap values (>70%) displayed below the corresponding branches. 
The basal lineage leading to mice/rats is highlighted in red. The marsupial Cd302 sequence from the Tasmanian devil was used as an outgroup. Right: Protein cartoon 
denotes the relative functional domains of mCd302 with the position of coding mutations unique to the rat/mouse specific lineage highlighted below.
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acid inducible gene I (RIG-I) and Toll-like receptor 3 (TLR3) (23). To 
determine whether mCd302 or mCr1l expression is modulated by either 
pathway, we treated murine primary hepatocytes with either IFN2a 
or the double- stranded RNA mimic polyinosinic:polycytidyl acid 
(polyI:C). Compared to control IRGs, we did not detect dysregulation of 
mCd302 or mCr1l mRNAs, indicating that their expression is constitutive 
and regulated by neither RIG-I nor TLR3 sensing pathways (Fig. 4E).
The human and rodent lineages diverged 80 to 90 million years 
ago (24), and infection of immunocompetent mice with HCV is not 
possible. The Cd302 gene is conserved throughout mammalian evo-
lution, and phylogenetic analysis of Cd302 coding sequences from 
representative mammalian species revealed reconstruction of the 
superordinal groupings predicted using multikilobase genomic loci 
(24). However, inconsistent with the organismal phylogeny, the 
positioning of the rat/mouse orthologs with other rodent species 
(guinea pig) was not supported, with these two species located 
antecedent to the placental grouping (Fig. 4F, left). This basal posi-
tioning of rat/mouse orthologs was supported by significant boot-
strap values. Closer inspection revealed fixation of nine unique 
nonsynonymous mutations on the rat-mouse lineage, distributed 
throughout the protein but concentrated in cytoplasmic tail (Fig. 4F, 
right). Together, these data indicate a unique evolutionary trajectory 
for rat/murine Cd302, with the fixation of multiple mutations on 
the rat:mouse branch giving rise to the incongruence between or-
ganismal and Cd302 phylogenies. This likely represents the signa-
ture of selection in response to pressure from pathogens and/or the 
possible acquisition of a novel biological function (e.g., antiviral 
restriction) or interaction partner (e.g., mCr1l). Phylogenetic analysis 
of mammalian Cr1l was not possible due to high levels of sequence 
divergence including indels (see Fig. 5B), coupled with the absence 
of a Cr1l ortholog in many mammal species.
Human hepatocytes lack CR1L mRNA expression but express 
CD302, limiting HCV infection
To explore whether CD302 and/or CR1L may have broader relevance 
for HCV permissiveness in humans, we aligned the human and 
murine protein orthologs of both factors. The hCD302:mCd302 
alignment revealed ~75% amino acid conservation, with hydro-
phobicity plotting identifying putative conserved transmembrane 
domains, implying membrane incorporation in both species (Fig. 5A). 
Differences between human and mouse were concentrated in the 
cytoplasmic tail domain. In contrast, hCR1L:mCr1l proteins shared 
only ~35% sequence identity, with large differences observed in the 
size of the translated protein. Hydrophobicity plotting identified a 
putative transmembrane region in murine Cr1l, although this do-
main was absent in human CR1L (Fig. 5B).
To investigate whether mRNA transcript abundance in hepato-
cytes is conserved between mice and humans, we conducted 
transcriptomic profiling of plated PHHs from multiple donors. 
While hCD302 transcripts were readily detected at similar levels to 
that observed in mice, hCR1L transcripts were virtually undetectable 
or completely absent, comparable to brain- or lung-specific mRNAs 
(Fig. 5C). Together, these data confirm constitutive expression of 
hCD302 mRNA in PHHs but the absence of hCR1L, suggesting that 
the combined potent and cooperative anti-HCV restriction provided 
by coexpression of both factors in mice is absent in the human liver. 
To test the human orthologs’ ability to restrict HCV infection, we 
ectopically expressed hCD302 and hCR1L in Huh-7.5 cells followed 
by infection with R-luc reporter HCV. Comparable to mCd302, we 
observed a potent reduction of intracellular RLU accumulation over 
a 4- to 96-hour time course for hCD302 (Fig. 5D). However, hCR1L 
mediated no effect on the ability of HCV to infect hepatoma cells. To 
determine whether expression of hCD302 in PHHs is modulated 
by the RIG-I or TLR3 sensing pathway, we treated PHHs with 
either IFN2a or polyI:C. Similar to mouse hepatocytes, we did not 
detect a dysregulation of hCD302 mRNA when compared to control 
genes, indicating that its expression is steady state and not regulated 
by either the RIG-I or TLR3 sensing pathways (Fig. 5E). The inability 
of the human ortholog of CR1L to restrict HCV, combined with 
an absence of CR1L mRNA in PHHs, highlights the differences 
between human and mouse with respect to intrinsic liver defenses: 
The combined cooperative antiviral restriction provided by both 
factors is absent in humans. Nonetheless, hCD302 alone was able to 
restrict HCV infection, which warrants further investigation.
C-type lectins make up a large superfamily of proteins with di-
verse functions. A unifying feature of this group of proteins is the 
CTLD fold, which is characterized by a double-loop structure that is 
stabilized by conserved disulfide bridges at the bases of these loops. 
The presence or absence of the so-called long loop region is used to 
divide CTLDs in two groups: Classical CTLDs (e.g., dendritic cell- 
specific intercellular adhesion molecule-3-grabbing non-integrin: 
DC-SIGN) have a long loop region, which is absent in the more com-
pact CTLDs (e.g., human CD44). The long loop region is involved 
in Ca2+-dependent carbohydrate binding and also in the binding of 
other ligands (25). Recently, the nuclear magnetic resonance (NMR) 
structure of the hCD302 extracellular domain was solved, showing that 
it comprises a canonical CTLD fold with a long loop region (Fig. 5F, 
right) (26). Superposition of an mCd302 CTLD homology model onto 
the CTLD structure of hCD302 revealed a large number of surface 
residues conserved between mouse and human CTLDs (Fig. 5F, left). 
This finding suggests conservation of ligand specificity between the 
mouse and human orthologs. In contrast, alignment of CPT regions 
highlights differences between human and mouse and may point to 
potential differences in downstream signaling between the species 
(Fig. 5F, bottom).
Enhanced murine hepatocyte susceptibility to an adapted 
HCV population
The minimal requirements for HCV entry into murine hepatocytes 
are the ectopic expression of human entry factors OCLN and CD81 
(12). Consequently, we generated humanized hOChep mice, which 
conditionally express human CD81 and OCLN in hepatocytes 
(hOCLN+/− hCD81+/−). To examine the relevance of endogenous 
Cd302 and Cr1l expression for HCV restriction, we explored whether 
knockdown of mCd302 and mCr1l in plated primary hOChep cells 
modulated the cellular response to infection and increased HCV 
permissiveness. To this end, we silenced mCd302 and mCr1l mRNA 
in plated hOChep, followed by HCV infection (strain Jc1) and tran-
scriptional profiling. The antiviral response to HCV infection was 
greater in plated hOChep previously treated with mCd302 and mCr1l 
targeting small interfering RNAs (siRNAs) when compared to 
hepatocytes transfected with control siRNAs (Fig. 6A). We did not 
observe this trend in PMH from a WT mouse lacking the human 
entry factors, indicating an HCV entry–associated process. These 
data suggested that mCd302 and mCr1l silencing facilitates more 
efficient HCV entry into murine hepatocytes, resulting in a concomi-
tant increase in the magnitude of the murine hepatocyte antiviral 
response. However, we did not observe subsequent viral replication 
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Fig. 5. Human-mouse differences in HCV restriction and hepatocyte expression. (A) Human CD302 and mouse Cd302 are transmembrane proteins. Hydrophobicity 
plotting reveals putative TM domains highlighted in gray. Highlighter plots positioned below visualize amino acid conservation between the species. Colored bars 
represent amino acid changes in the human homolog relative to the mouse protein sequence, while gray bars represent conserved residues. Black bars located above 
highlighter plot indicate indels. (B) Mouse Cr1l is a transmembrane protein, but human CR1L is not. (C) Human hepatocytes lack intrinsic hCR1L mRNA expression. Intrinsic 
mRNA expression of selected genes in PHHs from n = 3 donors. Cells with X represent genes with no detectable expression (RPKM = 0). (D) Human CD302 and restricts 
reporter HCV infection but human CR1L does not. HCV infection of Huh-7.5 cells overexpressing the indicated genes. Curves represent fold RLU increase over 4 hpi, and 
values presented are means of n = 5 experiments ± SEM. (E) Human CD302 mRNA is not inducible. Heatmaps showing fold change in mRNA expression of candidate genes 
in PHHs from n = 3 donors, which were either untreated or treated with IFN2a or PolyI:C. Fold regulation was compared to IFN or IFIT1 induction. (F) Extracellular domain 
homology model for mCd302. Left: Homology model based on the NMR structure of hCD302 (PDB 2NAN) is shown in cartoon surface representations with nonconserved 
residues highlighted in yellow. Right: Structural comparison of hCD302 with the canonical CTLD of DC-SIGN according to the classification of (25). Both proteins are shown 
in cartoon representation with the cysteine bridge specific for long-form CTLDs highlighted as orange sticks. The oligosaccharide LNFPIII bond to DC-SIGN in the repre-
sentative DC-SIGN-glycan complex structure (PDB 1SL5) is shown in ball-and-stick representation. Amino acid alignment of the human-mouse cytoplasmic tail region is 
positioned below.
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Fig. 6. Ablation of endogenous Cd302 expression in humanized murine hepatocytes enhances HCV permissiveness. (A) Silencing endogenous mCd302/mCr1l 
expression increases HCV uptake. Hepatocytes were transfected with the indicated siRNAs, followed 24 hours later by HCV infection. Numbers of genes >2-fold 
up-regulated were quantified at 24 hpi by comparison with uninfected hepatocyte transcriptomes transfected with the corresponding siRNAs. *IRGs determined using 
(22). (B) HCV strain p100pop exhibits enhanced replication in murine cells. MLT-MAVS−/−5H cells were infected with the indicated HCV strains. Intracellular vRNA and 
virion production were monitored, and data represent the means of n = 3 experiments ± SEM. Telaprevir (TVR). (C) Consensus mutations in the p100pop genome 
relative to parental Jc1. Data represent next-generation sequencing (NGS) coverage across the genome with nonsynonymous mutations detectable at a population 
frequency >50% highlighted. *Blue mutations are described in (27), gray mutations represent novel mutations identified by NGS, and the single green mutation was 
detected in the retained G-luc SP. (D) CRISPR-Cas9 ablation of endogenous Cd302 expression. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Western blot 
comparison of Cd302 protein expression in plated hepatocytes from the indicated mice. (E) Endogenous Cd302 knockout increases HCV uptake. Hepatocytes from the 
indicated mice were infected with p100pop, with and without ruxolitinib treatment. Intracellular core was determined after extensive PBS washing. Data represent means + 
SEM for n = 3 experiments. (F) Endogenous Cd302 knockout increases de novo HCV production. Hepatocytes from the indicated mice were pretreated with ruxolitinib, 
infected with either Jc1 or p100pop, and virion production monitored. Data represent mean values ± SEM from productive infections, which are presented as associated 
pie charts. Black, no infection; gray or pink, productive infection. (G) Cd302 knockout in improves intrahepatic HCV replication. Quantification of intrahepatic p100pop vRNA 
after intrasplenic inoculation. Data represent mean values + SEM from productive infections, which are presented as associated pie charts. ****P < 0.0001 and *P < 0.05.
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in plated hOChep. In contrast, siRNA targeting of ectopically ex-
pressed mCd302, mCr1l, or mCd302 and mCr1l in Huh-7.5 cells 
increased Jc1 replication (fig. S5). To overcome the observed block 
on HCV replication in murine hepatocytes, we compared fitness 
of parental HCV (strain Jc1) with an HCV population derived 
from Jc1 after 100 passages (p100pop) in Huh-7.5 cells, which ex-
hibits enhanced replicative fitness and partial resistance to IFN (27). 
Infection of mouse liver tumor (MLT) cells that ectopically express 
five human factors (CD81, SCARB1, CLDN1, OCLN, and APOE: 5H) 
coupled with blunted innate immune signaling due to ablation of 
mitochondrial antiviral-signaling protein (MAVS) expression (MLT/
MAVS−/−5H) (10) revealed significantly enhanced permissiveness to 
p100pop when compared to parental Jc1 (Fig. 6B). Suppression of 
p100pop replication in MLT/MAVS−/−5H was also demonstrated using 
teleprevir, an HCV NS3 protease inhibitor (Fig. 6B). This enhanced 
replicative fitness was correlated with 14 nonsynonymous mutations 
with >50% population frequency distributed throughout the p100pop 
open reading frame (ORF) (Fig. 6C). Although p100pop exhibits en-
hanced replicative capacity in murine liver cells, this strain was sus-
ceptible to mCd302/mCr1l restriction, albeit to a lesser extent than 
parental Jc1 (fig. S6).
Cd302 knockout modulates the murine hepatocyte 
transcriptome and increases HCV permissiveness
Silencing of mCd302 and mCr1l was effective in humanized mouse 
hepatocytes, leading to increased HCV uptake and a concomitant 
increase in innate cellular responses (Fig. 6A). However, because of 
high intrinsic expression, targeted mRNAs encoding functional 
mCd302 and mCr1l were still detected. To overcome this limitation, 
we deleted Exon 1 of the mCd302 locus in hOChep mice using CRISPR- 
Cas9 technology. Comparative Western blotting of primary he-
patocytes from hOChep and hOChep Cd302−/− mice revealed 
complete ablation of functional Cd302 protein expression (Fig. 6D). 
Unfortunately, mCr1l−/− knockout mice were not viable due to an 
embryonically lethal phenotype (28). To determine whether mCd302 
deletion modulated the intrinsic murine hepatocyte transcriptome, 
we performed global RNA-seq profiling on primary hepatocytes 
isolated from hOChep and hOChep Cd302−/− mice. These analyses 
revealed 289 significant DEGs in hepatocytes from hOChep Cd302−/− 
mice when compared to control hOChep mice, confirming a role for 
mCd302 in the regulation of constitutive gene expression levels in 
murine hepatocytes. Gene Ontology (GO) analyses revealed signif-
icant and overlapping dysregulation of genes associated with cellular 
defense and the inflammatory response, in addition to modulation 
of gene expression associated with hepatocyte metabolic processing 
(fig. S7, left). Analogous to overexpression of mouse Cd302/Cr1l in 
human cell lines where antiviral genes were generally up-regulated, 
ablation of endogenous Cd302 expression in mouse hepatocytes 
resulted in down-regulation of a subset of genes involved in virus 
defense and the inflammatory response (e.g., Apobec1, Isg20, Oasl1, 
Ccl7, and Cxcl9) (fig. S7, top right). In addition, dysregulation of 
genes associated with metabolic processing of lipids and fatty acids 
was also affected (e.g., Fabp4, Fabp5, and Plin5) (fig. S7, bottom right). 
A total of 159 of 289 DEGs were classified as IRGs.
To determine the effect of endogenous Cd302 knockout on HCV 
permissiveness, we infected either plated primary hepatocytes iso-
lated from hOChep or hOChep Cd302−/− mice with p100pop, blunting 
IFN responses with ruxolitinib. At 4 hpi, we detected higher levels of 
cell-associated HCV core protein in hOChep Cd302−/− hepatocytes 
when compared to hOChep controls (Fig. 6E, left). Cell-associated 
HCV core protein was reduced at 24  hpi likely due to vigorous 
IFN-dependent antiviral defenses. However, a significant difference 
was apparent between hepatocytes isolated from hOChep Cd302−/− 
and hOChep mice, with two- to fourfold greater cell-associated core 
detected, which could be further enhanced by JAK/STAT inhibition 
(Fig. 6E, right). These data suggested that ablation of endogenous 
Cd302 expression in humanized mouse hepatocytes increased infec-
tion by human-tropic HCV. Building on these data, we performed a 
time course comparison, infecting hepatocytes isolated from both 
hOChep and hOChep Cd302−/− mice with either Jc1 or p100pop after 
JAK/STAT inhibition, and monitored de novo virus production at 
24 to 144 hpi. No differences in virion release were observed be-
tween hepatocytes from hOChep and hOChep Cd302−/− mice infected 
with Jc1, with limited de novo HCV production detected (Fig. 6F, 
left). In contrast and despite differences observed between individual 
animals, de novo p100pop production was demonstrably increased 
in hepatocytes isolated from hOChep Cd302−/− mice when compared 
to parallel control hepatocytes from hOChep mice at 48 to 144 hpi, 
with up to 50-fold greater mean virus production observed (Fig. 6F, 
right). To investigate whether this observation could be replicated 
in vivo, we performed intrasplenic inoculation of hOChep or hOChep 
Cd302−/− mice with p100pop, with continued oral administration of 
ruxolitinib to suppress antiviral defenses mediated by JAK/STAT 
signaling (Fig. 6G). Serum and liver vRNA were assessed at 72 and 
120  hpi. No differences were observed in serum vRNA between 
hOChep and hOChep Cd302−/− mice at either time point, indicating a 
potential block on virus release in the murine liver. In contrast, at 
120 hpi, mean liver-resident vRNA was ca. 7-fold higher in hOChep 
Cd302−/− mice compared to hOChep animals, and only hOChep 
Cd302−/− mice displayed a significant increase of liver-resident virus 
load from 72 to 120 hpi (Fig. 6G). In summary, these data confirm 
that Cd302 contributes to the species barrier limiting HCV infection 
of murine hepatocytes, both in vivo and ex vivo.
DISCUSSION
The tolerogenic environment of the liver represents an attractive 
replication environment for pathogens enabling the establishment of 
chronic infection by HCV. Using cDNA library screening, we identified 
a lectin and a complement receptor, Cd302 and Cr1l, as previously 
unreported species barrier determinants contributing to HCV restric-
tion in the murine liver. Our data demonstrate that mCd302 and mCr1l 
expression is constitutive in murine hepatocytes and not inducible 
by IFN: These factors mediate protection independently of the IFN 
system. We observed differences in liver expression and the ability 
to restrict HCV between the murine orthologs and their human 
counterparts. The unique evolutionary trajectory of mouse:rat Cd302, 
which is largely due to differences concentrated in the short cyto-
plasmic tail, coupled with the lack of an interaction partner (Cr1l) 
to amplify any potential signal in humans, suggests that murine 
Cd302 has acquired a unique or enhanced antiviral function when 
compared to its human ortholog. Rodents (similar to bats) have high 
population densities in the wild and consequently represent reser-
voirs for many pathogens. Therefore, it is possible that mice might 
have evolved novel or enhanced antiviral strategies to cope with these 
more frequent pathogen exposures when compared to humans. 
Despite the differences observed between humans and mice, human 
CD302 mRNA was also abundant in PHHs, and ectopic expression of 
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human CD302 in hepatoma cells mediated an anti-HCV phenotype. 
Although outside the scope of this investigation, determining 
whether different allelic variants or differing hCD302 expression 
levels in the livers of HCV-infected patients is correlated with disease 
outcome (e.g., severity of liver disease or viral clearance versus per-
sistence) is currently the subject of further investigation.
Mechanistically, our data support a model where the murine 
transmembrane proteins Cd302 and Cr1l interact with each other 
and with virions to impede HCV cell entry. Competition with virus 
binding to canonical entry factors may impede virus trafficking to 
tight junctions and, in turn, productive infection. In addition, ectopic 
expression of murine factors in human hepatoma cells resulted in 
the cooperative induction of a noncanonical transcriptional program. 
Moreover, modulation of the intrinsic murine hepatocyte transcrip-
tome was observed upon Cas9 disruption of endogenous Cd302 ex-
pression. To further dissect these observations, we used ingenuity 
pathway analysis (IPA) to compare gene expression changes ob-
served between Huh-7.5 and Huh-7.5 [mCd302/mCr1l] cells with 
those observed between humanized hOChep and hOChep Cd302−/− 
PMHs. Modulation of mCd302 expression targeted common path-
ways in human and mouse liver cells: 16 significantly enriched ca-
nonical pathways were shared between both systems including four 
pathways associated with related nuclear receptors (NRs) (fig. S8A). 
NRs are known to regulate transcriptional programs that control 
host metabolic processes including lipid metabolism. In addition, 
NRs have been implicated in host-virus interactions, modulating 
susceptibility to both DNA and RNA virus infections (29). NRs 
have been shown to control both pro- and antiviral metabolic re-
sponses to HCV in PHHs (30). The top hit in both the human and 
mouse systems represents an NR pathway “LPS/IL-1 mediated inhi-
bition of retinoid X receptor (RXR) function” that influences down-
stream lipid and fatty acid metabolism. Detailed inspection of shared 
NR pathways identified significantly dysregulated molecules at multi-
ple pathway stages and contained shared and distinct molecules in 
both systems (fig. S8B). Corresponding changes in gene expression 
for targeted pathways in both systems highlights opposing tran-
scriptional dysregulation of gene subsets in these analogous in vitro 
and ex vivo systems (fig. S8C). Thus, in both human overexpression 
and in mouse knockout systems, gain or loss of Cd302 expression 
influences RXR NR signaling: RXR-dependent genes and their 
roles in lipid and fatty acid metabolism likely contribute to the re-
sulting antiviral state, as the HCV life cycle is tightly coupled to lipid 
and fatty acid metabolism.
Cas9 disruption of Cd302 expression in murine hepatocytes, 
humanized for productive HCV entry, increased permissiveness for 
an adapted HCV population both ex vivo and in vivo. We demon-
strate that p100pop, an HCV population that developed enhanced 
replication fitness and partial IFN resistance in human cells, also 
exhibits enhanced fitness in humanized mouse liver cell lines and in 
humanized PMHs when compared to its parent virus. The enhance-
ment of HCV permissiveness mediated by ablation of Cd302 liver 
expression in mice was only detectable when infection experiments 
were performed using p100pop, pointing to additional uncharac-
terized barriers to efficient HCV propagation in the murine liver. 
These barriers could represent missing or incompatible human co-
factors—or additional murine restriction factors targeting HCV. It 
is likely that the enhanced replication fitness and reduced IFN sen-
sitivity of p100pop enables a partial overcoming of these additional 
replication blocks that is not achieved by nonadapted strains. 
Therefore, p100pop represents a good starting point for development 
of more robust HCV mouse models, and stepwise adaptation of HCV 
to complete its full replication cycle in murine hepatocytes may also 
be possible. However, for the purposes of HCV vaccine development, 
these adapted viruses should retain the key attributes of strains that 
infect humans, e.g., receptor usage and immunogenicity.
The murine Cd302 gene is expressed in various myeloid cell types 
and different murine tissues, most prominently in the liver (20, 21). 
While a role in regulating myeloid cell migration was previously 
reported, the functional importance of hepatocyte-expressed mCd302 
remained elusive until now. Lectins expressed in myeloid cells play 
important roles in immune defenses (31). They recognize pathogens 
via their CTLDs and trigger responses such as endocytosis, phago-
cytosis, and release of pro- or anti-inflammatory cytokines. More-
over, the complement system is essential for pathogen clearance. Here, 
we report an unexpected cooperation between a hepatocyte-expressed 
lectin and a complement receptor in mice. This work highlights con-
vergence of lectin and complement systems for shaping liver intrinsic 
immunity and draws attention to a complex antiviral mechanism 
involving entry inhibition and metabolic reprogramming. Combin-
ing humanization of murine hepatocytes with ablation of a con-
stitutively expressed antiviral defense system—the mCd302/mCr1l 
axis—and using an adapted HCV population with enhanced repli-
cation capacity in murine cells opens new avenues for the develop-
ment of more robust HCV mouse models. Such a model will be of 
high value for development and safety testing of prophylactic vaccines 
to complement existing therapies for global control of and ultimate 
eradication of the HCV disease burden.
MATERIALS AND METHODS
Library generation, delivery, and screening
To generate a Mouse IFN-Induced Liver Library (MIILL), a single 
mouse was injected with IFN and euthanized at 4 hours post IFN 
induction. The liver was homogenized in TRIzol reagent (Invitro-
gen), and total RNA was extracted. The PolyA+ component of the 
total RNA was enriched using an Oligotex mRNA kit (QIAGEN). 
Using components from a SMART cDNA Library Construction Kit 
(Clontech), mRNA was reverse-transcribed into cDNA and size- 
fractionated before ligation into the lentiviral vector pV1. Ligated 
fractions were electroporated into ElectroMAX DH5 (Invitrogen) 
cells according to the manufacturer’s specifications, and resulting 
colonies were sequenced to ascertain the library quality. Ligated frac-
tions that contained high percentages of diverse full-length mouse 
ORFs were pooled and electroporated before solid phase amplifica-
tion in approximately 8 liters of medium. Before solid phase ampli-
fication, the MIILL contained 4 × 106 independent clones. After solid 
phase amplification, the pV1 MIILL was extracted from transformed 
bacteria using a Maxiprep protocol (Macherey Nagel), aliquoted, and 
stored at −20°C. The library was packaged into VSV-G–enveloped 
psuedoparticles via three-plasmid transfection into 293T cells. 
VSV-G, HIV-1gag/pol, and pV1 MIILL plasmids were transfected 
in equimolar amounts using Lipofectamine 2000 (Invitrogen), and 
supernatants were harvested at 24 and 48 hours after sodium butyr-
ate induction. Titers of MIILLpps were calculated via median tissue 
culture infectious dose (TCID50) limiting dilution onto HeLa-TZMbl 
cells. Cells were fixed and stained 72 hpi, and MIILLpps were aliquoted 
and stored at −80°C. Permissiveness of different cell lines for MIILLpp 
transduction was determined via fluorescence-activated cell sorting 
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(FACS) using pV1 green fluorescent protein–containing pseudoparticles. 
We delivered our MIILL (one to two particles per cell) to highly 
permissive n4mBid hepatoma cells. These cells are modified Huh-
7.5 cells, which undergo programmed cell death upon HCV replica-
tion (13). Iterative rounds of selection were performed with WT 
HCV [Jc1: multiplicity of infection (MOI) 50], and surviving cells 
were expanded. Permissiveness to HCV/coronavirus (CoV) infec-
tion was assessed using R-luc reporter viruses.
RNA-seq
Total RNA from primary cells and cell lines was extracted using a 
NucleoSpin RNA kit (Macherey Nagel) or TRIzol reagent (Invitrogen) 
according to the manufacturer’s instructions. RNA quality checking 
was performed using an Agilent Bioanalyzer, and sequencing libraries 
were generated using a ScriptSeqv2 kit (Illumina) according to the 
manufacturer’s instructions. RNA-seq was performed using the Illu-
mina HiSeq 2500 or NovaSeq platforms. Transcriptomic analyses 
were performed using CLC Genomics Workbench (QIAGEN). Raw 
FASTQ files were mapped against the hg19 human or mm9 Mus 
musculus reference genomes with annotated gene and mRNA tracks. 
Gene expression was calculated for individual transcripts as RPKM, 
and identification of DEGs was performed. GO analyses were con-
ducted using the GO resource (http://geneontology.org/). Significantly 
enriched GO categories were identified using the PANTHER Classi-
fication system (http://pantherdb.org/). P values for GO categories 
were adjusted for multiple testing using the Bonferroni correction.
vRNA isolation, NGS library preparation, and Illumina 
sequencing of HCV p100pop
Isolated vRNA was used for Illumina library preparation using a 
modified protocol of the NNSR priming method (32). Briefly, for the 
RT, 5 l of RNA and 100 pmol NNSR_RT primer (gctcttccgatctct-
NNNNNN) were heat denatured at 65°C for 5 min and chilled on ice. 
The reactions were supplemented with first-strand synthesis buf-
fer, 10 mM dithiothreitol, 0.05 mM deoxynucleotide triphosphates 
(dNTPs), 20 units of RiboLock ribonuclease (RNase) inhibitor, and 
200 units of Superscript III reverse transcriptase (Thermo Fisher Sci-
entific). Volumes were standardized to 20 l, and reactions were in-
cubated at 45°C for 30 min followed by heat inactivation at 70°C for 
15 min. The nucleic acids were purified with magnetic beads, and the 
RNA was digested with RNase H [New England Biolabs (NEB)] for 
20 min at 37°C. After bead purification, cDNA samples were subject-
ed to second-strand synthesis at 37°C for 30 min in a 50-l final reac-
tion volume containing the following: NEB buffer 2, 0.125 mM 
dNTPs, 5 units of 3′-5′exo-Klenow Fragment (NEB), and 200 pmol 
NNSR-2 primer (gctcttccgatctgaNNNNNN). After magnetic bead 
purification, the double-stranded cDNA served as the template for 
PCR amplification to obtain the barcoded Illumina libraries. The 
PCRs were performed using the NEBNext Ultra II Master Mix (NEB) 
containing 25 pmol NNSRnest_ind_N (caagcagaagacggcatacgagat-
NNNNNNgtgactggagttcagacgtgtgctcttccgatctga) and NNSR_Illumina 
(aatgatacggcgaccaccgagatctacactctttccctacacgacgctcttccgatctct) primers, 
each using the following cycling conditions: 98°C for 10 s; 5 cycles of 
98°C for 10 s, 55°C for 30 s, and 68°C for 30 s; and 15 cycles of 98°C for 
10 s, 65°C for 30 s, and 68°C for 30 s. The resulting 300- to 700–base 
pair (bp) DNA smears were isolated from 1.5% agarose gels with the 
Zymoclean Gel DNA Recovery Kit (Zymo Research), quantified with 
qPCR using the NEBNext Library Quant Kit for Illumina (NEB), and 
sequenced on a MiSeq instrument with a paired-end 2 × 300 setting.
Stable cell line generation
For ectopic expression of human or murine genes, gBlock gene frag-
ments were ordered (Integrated DNA Technologies) and cloned into 
the lentiviral vector pWPI (Addgene) via restriction cloning (encod-
ing either blasticidin or puromycin resistance genes). Correct orien-
tation and nucleotide sequences of inserts were verified by Sanger 
sequencing (GATC). Lentiviral plasmids were packaged into VSV- 
G–enveloped pseudoparticles via three-plasmid transfection into 
293T cells. VSV-G, HIV-1gag/pol, and pWPI plasmids were trans-
fected in equimolar amounts using Lipofectamine 2000 (Invitrogen), 
and supernatants were harvested at 24 and 48 hours after sodium bu-
tyrate induction. Pooled supernatants were filtered (45-m pores) 
and used to transduce 2 × 105 Huh-7.5 cells. Seventy-two hours after 
transduction, selection markers were added to media, and surviving 
cells were expanded.
Cell lines
All cancer cell lines were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM) (Invitrogen) supplemented with nonessential amino 
acids (Invitrogen), 2 mM l-glutamine (Invitrogen), and 10% fetal calf 
serum (FCS) (PAA Laboratories GmbH). For selection of lentiviral 
transduced cell lines, blasticidin (5 g/ml; Invivogen) or puromycin 
(2 g/ml; Sigma-Aldrich) was added. To induce polarization, cells 
were trypsinized and resuspended in DMEM + 10% fetal bovine 
serum (FBS) for a final concentration of 1 × 105 cells/ml. Thawed 
Matrigel (Growth Factor Reduced, Phenol Red-free; Sigma-Aldrich) 
and cells were combined in equal parts, seeded onto coverslips in 24-
well plates (75 l per well), and then incubated at 37°C until polym-
erized. DMEM + 10% FBS was added to each well, and cells were 
cultured for 7 days, changing the media every other day.
Viruses
WT, p100pop (provided as a gift from E. Domingo, Madrid, Spain), 
and R-luc and F-luc reporter HCV viruses were produced as previ-
ously described. Human CoV 229E R-luc reporter virus was pro-
vided as a gift from V. Theil (Bern, Switzerland). For DiD labeling, 
HCV stocks were concentrated using PEG (polyethylene glycol 8000; 
Thermo Fisher Scientific) precipitation resuspended in serum-free 
media and then labeled with 5 l of DiD (Invitrogen) per 1-ml con-
centrated virus for 90 min. The virus was then added to a 10 to 60% 
weight/volume iodixanol gradient (OptiPrep, Sigma-Aldrich) and 
centrifuged for 16.5 hours at 34,000 rpm (4°C). The resulting gradi-
ent was separated into 1-ml fractions; each was assayed for specific 
infectivity (33). Fractions with acceptable specific infectivity (<10) 
were purified via Amicon Ultra 100K filters (Millipore).
Huh-7.5 cells stably expressing SEC14L2 and murine restriction 
factors were infected with serum from acute-phase or post-transplant 
patients with HCV as previously described (15). Briefly, cells were seeded 
into 24-well plates at a density of 50,000 cells per well and grown overnight. 
The cells were then infected with 25 l of patient serum diluted in 
500 l of DMEM containing 10% FBS, 1× non-essential amino acids 
(NEAA), and epidermal growth factor (EGF; 50 ng/ml). After overnight 
incubation with serum, cells were rinsed twice with 1× phosphate-buffered 
saline (PBS) and fed with 500 l of fresh medium containing 10% FBS, 
1× NEAA, and EGF (50 ng/ml). Two days later, the cells were transferred 
to the 12-well plates and grown for another 3 days before they were 
harvested for RT-qPCR.
HEV constructs based on the genotype 3 Kernow C1 strain p6, 
S10-3 cells, and anti-ORF2 antibody were a gift from S. Emerson, 
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National Institutes of Health. To prepare the vRNA for transfection, 
HEV plasmids p6, p6Gluc, and p6Gluc/GAD active site mutant (34) 
were linearized with the restriction enzyme Mlu I, and in vitro tran-
scription was performed using the mMESSAGE mMACHINE Kit 
(Life Technologies). Two hundred nanograms of in vitro–transcribed 
vRNA was transfected into 1 × 105 S10-3 cells per well of a 12-well 
cell culture plate using the TransIT-mRNA transfection kit (Mirus 
Bio LLC, Madison, WI). For cells transfected with the subgenomic 
replicon p6GLuc ± GAD, medium was changed every 24 hours and 
harvested for GLuc quantification. Full-length virus p6 was harvested 
as previously described (35). HEV focus- forming units were quan-
tified by staining for anti-HEV capsid ORF2.
Huh-7.5 cells stably expressing murine restriction factors were in-
fected with DENV (16681 strain) (MOI 0.5), YFV 17D vaccine strain, the 
parental Asibi strain (MOI 1), and WNV (lineage 1 strain, WNV-TX02) 
(MOI 0.5). Cells were stained for flow cytometry using the following: 
rabbit polyclonal anti-NS3 antibody (GeneTex, cat. no. GTX124252, 
1:500) for DENV, mouse monoclonal antibody (Santa Cruz Biotechnology, 
cat. no. SC58083, 1:500) for YFV, and mouse monoclonal anti-NS1 
antibody (BEI Resources, cat. no. 10145, 1:500) for WNV.
For RSV F-luc virus production, Hep2 cells (American Type Cul-
ture Collection CCL-23) were grown in advanced MEM medium 
(Thermo Fisher Scientific, Waltham, MA) supplemented with 10% 
heat-inactivated FCS (Capricorn Scientific, Ebsdorfergrund, Germany), 
2 mM l-glutamine (Thermo Fisher Scientific, Waltham, MA), peni-
cillin and streptomycin (100 U/ml; Thermo Fisher Scientific, Waltham, 
MA), and 1× nonessential amino acids (Thermo Fisher Scientific, 
Waltham, MA) at 37°C in humidified air with 5% CO2. HEp2 cells 
were seeded in 15-cm cell culture dishes (Corning Incorporated, Life 
Sciences, Oneonta, NY) to reach 60 to 70% confluence the next day. 
Twenty-four hours later, medium was removed, and 5 ml of FCS-free 
advanced minimal essential media (adv. MEM) containing 4 × 
105 TCID50/ml of recombinant human respiratory syncytial virus 
(HRSV) subtype A F-luc reporter virus (provided by J.-F. Éléöuet) was 
added. Cells were incubated at 37°C and gently shaken for 4 hours. 
Medium was replaced with adv. MEM containing 2% FCS followed 
by further incubation at 37°C until syncytia formation was prominent. 
Supernatant and cells were harvested, supplemented with 10% of 
virus stabilizer buffer [1 M MgSO4 and 0.5 M Hepes (pH 7,5)], and 
vortexed vigorously for 2 min to release cell- attached virus particles. 
Debris was removed by centrifugation at 1000g for 5 min, and cell-free 
supernatant was frozen in −80°C cold ethanol for 12 hours and then 
transferred to long-term storage at −80°C.
Isolation of primary hepatocytes
Hepatocytes were isolated from mice by a modified two-step Liber-
ase perfusion (36). Briefly, mice were anesthetized using Ketamine 
(Albrecht) and Rompun (Bayer). The body cavity was opened, and 
a catheter was placed into the portal vein and connected to a flow 
pump, which pumped media prewarmed at 37°C from a water bath 
into the catheter, and the vena cava was cut. The liver was first per-
fused with Earle’s balanced salt solution (EBSS) (Gibco) solution 
containing 0.5 mM EGTA (Sigma-Aldrich) and 10 mM Hepes buf-
fer (Sigma-Aldrich). Subsequently, EBSS supplemented with 10 mM 
Hepes buffer and Liberase (100 g/ml; Roche) was applied for enzy-
matic digestion of the tissue at 37°C. After digestion for 10 to 12 min, 
the liver was carefully disconnected and tissue was manually dis-
rupted with sterile scissors and scalpel in DMEM (Gibco) contain-
ing 10% FCS (PAN-Biotech). The suspended hepatocytes were passed 
through a 100-m nylon filter into 50-ml Falcon tubes. The cell sus-
pensions were centrifuged twice at 300 rpm for 5 min at 4°C, and 
cell pellets were resuspended in ice-cold DMEM containing 10% 
FCS. Cell viability was tested by trypan blue (Fluka) before plating 
on collagen-coated six-well dishes. Approximately 5 × 105 cells were 
plated per well, and supplemented hepatocyte culture media (HCM) 
(Lonza) were used to maintain primary hepatocytes in culture.
Plated PHHs were obtained from the Department of General, 
Visceral, and Transplant surgery at Hannover Medical School and 
cultured as previously reported (37). Hepatocytes were isolated from 
liver tissue from donors undergoing partial hepatectomy and were 
obtained with written informed consent approved by the Ethics 
Commission of Hannover Medical School (Ethik-Kommission der 
MHH, no. 252-2008). Again, supplemented HCM media (Lonza) 
were used to maintain primary hepatocytes in culture.
HCV infection assays
Initial HCV infection screening of murine hits using F-luc reporter 
HCV (Jc1) were conducted in 96-well plates (three technical repli-
cates per condition) at MOI 0.1. Subsequent characterization was 
performed using R-luc reporter HCV (Jc1), again conducted in 96-
well plates (three technical replicates per condition) at MOI 0.05. A 
minimum of three biological replicates were performed for all ex-
periments. For HCV infection of plated murine hepatocytes, 5 × 105 
TCID50 units per six-well dish were used for WT Jc1 or p100pop 
virus. Viral supernatant was collected each day and replaced with 
fresh HCM media containing 10 M ruxolitinib (AdipoGen, Leistel, 
Switzerland). The viral supernatants were then tested for infectious 
viral particle production using the TCID50 assay.
Immunofluorescence and immunohistochemistry staining
Immunofluorescence and imaging of PMHs and Huh-7.5 cells over-
expressing restriction factors were performed as follows. PMHs were 
seeded on collagen-coated glass coverslips in 24-well dishes. Huh-7.5 
cells overexpressing murine Cd302 or Cr1l were seeded on uncoated 
glass coverslips (5 × 104 cells per well) and grown until they reached 
about 80% confluence. Fixation was achieved by incubating the cells 
in chilled (4°C) 95% ethanol + 5% acetic acid for 10 min at room 
temperature. After two washes in PBS, cells were permeabilized for 
10 min at room temperature in PBS + 0.1% Triton X-100 and rinsed 
twice again in PBS. To block potential nonspecific antibody binding, 
coverslips were incubated in a 5% solution of goat serum in PBS for 
1 hour at room temperature. To detect murine Cd302, 5 g/ml of an 
-Cd302 monoclonal (Cd302/Clec13a; R&D Systems, rat IgG1) was 
used. To detect murine Cr1l, a polyclonal antibody solution at a con-
centration of 2 g/ml (Crry M180; Santa Cruz Biotechnology, rabbit 
IgG1) was used. Incubation of these solutions was performed at room 
temperature for 1 hour or overnight at 4°C. After three washes in 
PBS, the primary antibodies were detected by fluorophore-conjugated 
anti-rat [Alexa Fluor 488 rabbit anti-rat immunoglobulin G (IgG); 
Life Technologies] and anti-rabbit [Alexa Fluor 568 donkey anti-rabbit 
IgG (H + L), Invitrogen] antibodies, respectively, at a concentra-
tion of 2 g/ml in blocking solution for 1 hour at room temperature 
and protected from light. After washing off excess secondary anti-
bodies with PBS twice for 5 min, staining of the nuclei was performed 
using a 0.5-g/ml 4′,6-diamidino-2-phenylindole (DAPI) solution in 
H2O. One final wash in H2O was then followed by mounting of the 
coverslips in ProLong Gold Antifade Mountant (Thermo Fisher Sci-
entific) and drying overnight at room temperature protected from 
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light. For imaging, an inversed confocal laser scanning microscope 
(Olympus FluoView 1000) with a ×100 magnification objective was 
used with FluoView 1000 imaging software (Olympus). Microscope 
settings, including laser intensity and exposure time, were identical for 
the target protein (Cd302 or Cr1l), the isotype control, and the sec-
ondary only control, respectively.
Matrigel-polarized organoids were infected with DiD-HCV, in-
cubated on ice for an hour, then transferred to 37°C (time of tem-
perature shift: t = 0), and fixed in 3.6% paraformaldehyde (PFA) at 
various points post-temperature shift. Cells were fixed for 20 min in 
PFA, permeabilized with 1% Triton X-100/PBS for 10 min, washed 
with 0.1 M glycine in PBS three times for 10 min each, and then 
incubated in blocking solution for 2 hours (wash buffer: 0.1% bo-
vine serum albumin, 0.2% Triton X-100, and 0.005% Tween 20 in 
PBS + 20% goat serum). Samples were incubated at 4°C overnight 
with anti–ZO-1 antibody (1:500; Invitrogen) and then allowed to 
reform at room temperature for 10 min. Samples were washed three 
times for 20 min each time, with wash buffer, and then incubated 
for 1 hour at room temperature with Alexa Fluor–conjugated sec-
ondary antibody (488) in blocking solution. Coverslips were washed 
three times as above and then mounted on slides with DAPI pro-
long gold (Invitrogen). Slides were imaged using an Olympus Disk 
Scanning Unit Spinning Disc Confocal with a 100× numerical aper-
ture 1.45 oil-immersion objective and Hamamatsu back thinned 
electron multiplying charge-coupled device camera; images were 
captured using SlideBook imaging software; intensification was set 
to 255, and z-stacks of the organoids were acquired with 0.3-m 
slices. After acquisition, images were quantified for colocalization 
in ImageJ with RGB profiler (C. Laummonerie) and colocalization 
highlighter. Images were selected from z-stack slices, separated into 
channels, adjusted for contrast and brightness, smoothed, and finally 
reassembled.
For the detection of Cr1l (Crry) in formalin-fixed and paraffin- 
embedded murine tissue, the antibody sc30214 (Santa Cruz Bio-
technology) was diluted 1:400, and antigen retrieval was performed 
by 20′ microwave/citrate cooking. As a negative control, the primary 
antibody was replaced in the same concentration with rabbit serum, 
and for all slides, a biotinylated goat anti-rabbit secondary antibody 
was used. For visualization, 3,3′-diaminobenzidine was applied.
Flow cytometry
A confluent monolayer of cells was detached using trypsin with the 
exception of PMHs, which were detached using EDTA (1 mM). Cells 
were pelleted and subsequently resuspended in FACS buffer (1% FCS 
in PBS). Approximately 1 × 106 Huh-7.5 cells or CHO-745 cells over-
expressing mouse restriction factors or PMHs endogenously express-
ing these factors were stained for 30 min at 4°C with unconjugated 
primary monoclonal antibodies specific for Cd302 (Cd302/Clec13a; 
R&D Systems, rat IgG1) and Cr1l (Crry M180; Santa Cruz Biotech-
nology, rabbit IgG1 or anti-Cr1l biorbyt and rabbit IgG) diluted in 
FACS buffer to 1.6 g/ml. To analyze the endogenous expression of 
human receptors present on Huh 7.5 cells, primary unconjugated an-
tibodies specific for scavenger receptor class B type 1 (Novus; poly-
clonal rabbit antibody), Claudin 1 (R&D Systems; rat IgG), and OCLN 
(Life technologies; mouse IgG) were diluted in FACS buffer to 20, 
10, and 1 g/ml, respectively. For CD81, directly coupled antibody to 
fluorescein isothiocyanate (FITC) was used (BD Pharmingen, JS-81). 
Subsequently, cells were washed with FACS buffer thrice, and 
bound antibodies were detected by incubation for 30 min at 4°C 
with specific secondary antibody conjugated to an Alexa Fluor (Life 
Technologies), namely, anti-mouse Alexa Fluor 488, anti-rabbit 
Alexa Fluor 647, and anti-mouse Alexa Fluor 647 at a dilution of 
1:1000 in FACS buffer and rat-specific secondary antibody conju-
gated to phycoerythrin (eBioscience) at a dilution of 1:200 in FACS 
buffer. The following isotype controls were used: rat isotype IgG 1 
(R&D Systems), rabbit polyclonal (Abcam), and isotype FITC mouse 
IgG1 (BD Pharmingen) at the same concentration as primary anti-
bodies. Stained cells were washed with FACS buffer thrice, resus-
pended in FACS buffer, and analyzed immediately using an Accuri 
C6 cytometer (BD Biosciences), and data were analyzed using FlowJo 
software (Tree Star).
Immunoprecipitation
The Huh-7.5 N-HA-HA-L-Cd302/Cr1l cell line was obtained by 
lentiviral transduction of Huh-7.5 cells with the pWPI-N-HA-HA-
L-Cd302 plasmid, selection with blasticidin (5 g/ml) and subse-
quent lentiviral transduction of the pWPI-Cr1l plasmid, followed by 
a double selection with blasticidin and puromycin (2.5 g/ml). To 
test the interaction between Cd302 and Cr1l, half a confluent 15-cm 
dish of Huh-7.5/empty, Huh-7.5/Cr1l, or Huh-7.5 N-HA-HA-L-
Cd302/Cr1l cells was harvested by trypsinization and lysed in 250 l 
of IP buffer [50 mM Hepes (pH 7.4), 150 mM NaCl, 1 mM CaCl2, 
10% glycerol, 1% NP-40, and complete EDTA-free protease inhibi-
tor cocktail 1× (Roche no. 04 693 124 001)] for 30 min on ice. Cell 
nuclei were removed by centrifugation (10 min at 20,000g), and 5 l 
of the supernatant was kept as an input for the Western blot. The 
anti-HA resin (Sigma-Aldrich; A2095) was washed twice in PBS (30 s 
at 12,000g), and 25 l was used per IP. Cleared lysates and resin were 
incubated together overnight on a rotating wheel at 4°C. Afterward, 
the beads were washed twice quickly (no incubation time), twice 
with 5-min incubation periods on a rotating wheel, and once quick-
ly with IP buffer (without protease inhibitor). After a final quick 
wash in water, the proteins were eluted in reducing Laemmli buffer 
(7 min at 70°C) and loaded on an SDS–polyacrylamide gel electro-
phoresis for separation and transfer on a polyvinylidene difluoride 
membrane. The membrane was probed with rat anti-Cd302 anti-
body (1/250) and rabbit anti-Cr1l antibody (1/250), followed by the 
secondary goat anti-rat IRDye 800CW and donkey anti-rabbit 
IRDye680RD (both at 1/15,000; LI-COR). Signal intensities were 
read with the Odyssey CLx imager (LI-COR).
RT-qPCR
Total cellular RNAs from cell lines or primary cells were isolated 
using a NucleoSpin RNA Kit (Macherey Nagel) according to the 
manufacturer’s instructions. Total RNA concentrations were quan-
tified using a NanoDrop spectrophotometer (PEQLAB). Subse-
quently, 500 ng to 1 g of total RNA was reverse-transcribed into 
cDNA using a PrimeScript First Strand cDNA Synthesis Kit (Takara) 
in accordance with the kit instructions. Reactions were performed in 
triplicate. Subsequent qPCR of cDNAs was performed using ×2 
SYBR MasterMix (Takara) and the LightCycler 480 system (Roche). 
Validated primer pairs for all mRNAs were taken from PrimerBank 
(https://pga.mgh.harvard.edu/primerbank/). For quantification of 
fold regulation in gene expression, calculations were performed us-
ing the CT method (QIAGEN Data Analysis Center: https://www.
qiagen.com/de/shop/genes-and-pathways/data-analysis-center- 
overview-page/). For normalization, ACTB and HPRT were used as 
reference genes.
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Western blotting
Cells were washed with PBS and lysed in radioimmunoprecipitation 
buffer [0.3 M NaCl, 20 mM tris-HCl (pH 8), 1% sodium deoxycho-
late, 0.1% SDS, and 1% Triton X-100] for 30 min on ice. Total protein 
content was determined by Bradford assay. Equal protein amounts 
for each sample were mixed with 2× denaturing protein sample buffer 
[200 mM tris-HCl (pH 8.8), 5 mM EDTA, 0.1% bromophenol blue, 
10% sucrose, 3.3% SDS, and 2% 2-mercaptoethanol], heated for 5 min 
at 98°C, loaded onto a 11% SDS gel, and resolved by electrophoresis. 
Subsequently, proteins were transferred to a polyvinylidene difluoride 
membrane, which was then blocked with 5% milk in PBS containing 
0.5% Tween 20 for 1 hour at room temperature. The membrane was 
then incubated with either -mCrry/mCr1l (1:250; Santa Cruz Bio-
technology), -mCd302 (1:250; R&D Systems), or --actin (1:1000; 
Sigma-Aldrich) followed by incubation with secondary antibody cou-
pled to horseradish peroxidase (Sigma-Aldrich). Bound antibodies 
were detected with the ECL Plus Detection System (GE Healthcare).
HCV pseudoparticles
Retroviral pseudoparticles were generated with surface glycoproteins 
derived from HCV E1E2 (isolates Con1, genotype 1b, or UKN2B2.8, 
genotype 2b) or an empty vector as negative control (pcDNA EMPTY). 
Packaging construct pHIT60 encoding MLV gag/pol was cotrans-
fected with the retroviral vector (pRV-F-Luc) and the individual en-
velope expression constructs using polyethylenimine (PEI) (Polyplus, 
Illkirch, France). Twenty-four hours later, sodium butyrate (10 mM) 
was added to transfected cells and incubated for 6 to 8 hours. At 
48 hours after transfection, virus-containing culture fluids were har-
vested, filtered through a 0.45-m pore size filter (VWR International, 
USA), and used to inoculate target cells.
HCV core enzyme-linked immunosorbent assay
Murine hepatocytes plated in six-well dishes were harvested after in-
fection via aspiration of media, washed three times in PBS, and lysed 
via addition of 300 l of 1% Triton X-100 in PBS with added protease 
inhibitor (Roche). Lysates were subsequently diluted in 1% Triton 
X-100 in PBS, and cell-associated HCV core was quantified by an 
automated chemiluminescent microparticle immunoassay (Architect 
HCV Ag, Abbott, Germany).
Phylogenetic analysis
Phylogenetic analysis of mammalian Cd302 sequences was performed us-
ing the maximum likelihood method implemented in MEGA7 (38) based 
on the data-specific model. The significance of groupings was assessed 
using the bootstrap approach with 1000 pseudoreplicates performed. The 
tree with the highest log likelihood is presented, with significant bootstrap 
values (70%) assigned to the corresponding branch. The tree was generat-
ed under a GTR +  + I model of substitution whereby discrete Gamma 
distribution () was used to model evolutionary rate differences among 
sites (four rate categories). The proportion of invariant sites (I) was also 
incorporated into the reconstruction. The phylogeny is drawn to scale, 
with branch lengths proportional to the number of substitutions per site. 
All positions containing gaps and missing data were eliminated from the 
analysis. The dataset incorporated Cd302 sequences from 24 species, and 
a total of 603 nucleotide positions were included in the final analysis.
Canonical pathway analysis
Canonical pathway analyses were performed using IPA (QIAGEN). 
Data input consisted of an Excel sheet containing Ensembl identifiers, 
P values, FDR P values, fold change, and log fold change values for 
genes, as previously determined with CLC Genomics Workbench. 
In general, default settings were used for all categories, but species 
was set to “human” for data from Huh-7.5 cells ectopically express-
ing murine factors and “mouse” for data from PMHs. FDR P value 
significance threshold was set to 0.05 for genes included in the sub-
sequent analysis. Z scores were calculated on the basis of the expres-
sion fold change.
Generation of mouse lines
Mice with hepatocyte-specific expression of human occludin and 
Cd81 (hOChep, hOCLN+/− hCD81+/−) were generated by breeding 
hOCcon mice with AlbCre mice (39). hOCcon mice comprise an in-
verted, Cre-activatable expression cassette for human occludin and 
CD81 and were generated upon Flp-based targeted integration of 
the Rosa26 locus (40) using the following targeting cassette: Fwt – 
IPS-RFP – PCAGGS-loxL3-loxP-(hOCLN-IRES- hCD81)inv-loxL3inv- 
loxPinv – IRES – F5. Knockout of Cd302 (Cd302−/−) was achieved by 
CRISPR-Cas9–mediated excision of 40 bp including the initiation 
codon (c − 29) − (c + 11) in C57BL/6 zygotes using guide RNA target 
sites CACCCGACAAGCACCGCCCC and TGCACTCTCCGGG-
GCGCGGC, applying a previously published protocol (41). hOChep 
Cd302−/− animals were generated by breeding. Genetically modified 
mice were generated with the approval of the ethical board of the 
Lower Saxony State Office for Consumer Protection and Food Safety, 
Oldenburg, Germany.
CHO binding assay
CHO-745 cells were either left untransfected or PEI-transfected 
with pWPI-SCARB1, pWPI-mCd302, pWPI-mCr1l, or both pWPI- 
mCd302 and pWPI-mCr1l together. Cell surface expression levels 
were analyzed 48 hours after transfection using FACS. At 48 hours 
after transfection, CHO-745 cells were incubated with HCVcc (Jc1) 
particles for 2 hours at 37°C. After binding, the cells were washed 
extensively with PBS, total RNA–isolated, and HCV RNA–quantified 
using RT-qPCR.
In vivo infections
hOChep or hOChep Cd302−/− mice were inoculated intrasplenically 
with 100 l of concentrated DMEM containing 1.2 × 107 TCID50 
units of HCV p100pop virus. Ruxolitinib treatment was orally ad-
ministered every 8 to 12 hours (starting 4 hours before infection) at 
a dose of 100 mg/kg, and ruxolitinib (Ambeed, IL, USA) was dis-
solved in 20% dimethyl sulfoxide (DMSO) and 50% PEG 400 (seven 
doses for animals tested for 3 days and 13 doses for animals tested 
for 5 days). At the end of each experiment, animals were euthanized, 
and blood and liver samples were processed for further analysis. All 
procedures were performed according to European and Belgian leg-
islation and were approved by the Animal Ethics Committee of the 
Faculty of Medicine and Health Sciences of Ghent University. 
Snap-frozen whole or partial livers from individual mice were ho-
mogenized in RA1 lysis buffer from the Macherey Nagel NucleoSpin 
RNA Isolation kit at a concentration of 100 mg/ml. Total RNA ex-
traction was then performed on 350 l according to the manufactur-
er’s instructions. To further enrich viral RNA, an HCV capture assay 
was performed whereby 10 g of extracted total RNA was diluted in 
200 l of TEN buffer [10 mM tris-HCl (pH 8.0), 1 mM EDTA, and 
100 mM NaCl] and incubated for 5 min at 75°C with subsequent addi-
tion of 0.5 g of HCV-specific biotinylated capture DNA (BIOTEG-AAG 
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TAT ACT CCG CCA ACG ATC TGG CCG CCG) followed by vor-
texing and further incubation for 5 min at 65°C. Meanwhile, MACS 
columns were equilibrated according to the manufacturer’s instructions 
(MACS Streptavidin Kit, Miltenyi Biotec). One hundred microliters 
of MACS streptavidin microbeads was then added to the mix and 
incubated for further 2 min at 65°C. The solution was then added 
to the MACS columns and washed with 5 × 200 l with TE buffer 
[10 mM tris-HCl (pH 8.0) and 1 mM EDTA], and captured RNA 
was then eluted with 150 l of H2O preheated to 80°C. Drops 2 to 4 
were collected (approximately 50 l) for analysis by RT-qPCR. Cap-
tured RNA from the liver samples were analyzed by RT-qPCR using 
the Roche LightCycler 480 RNA Master Hydrolysis Probes kit (Roche), 
primers (5′-TCTGCGGAACCGGTGAGTA-3′ and 5′-GGGCAT-
AGAG TGGGTTTATCCA-3′) and probe (5′-6FAM-AAAGGAC-
CCAGTCTTCCCGGCAA-TMR-3′), according to the manufacturer’s 
conditions.
Cd302 structure modeling
A homology model of the extracellular domain of mCd302 was gen-
erated on the basis of the NMR structure of the hCD302 extracellu-
lar domain [Protein Data Bank (PDB) 2NAN] using the Phyre2 web 
server (42). Nonconserved residues were mapped on the surface 
of mCd302 according to a pairwise sequence alignment obtained 
via Clustal Omega (43). Structure figures were prepared with 
PyMOL (The PyMOL Molecular Graphics System, version 1.8.0.3, 
Schrödinger, LLC).
Statistical analysis
Statistical tests were performed in GraphPad Prism v8.0 on data 
generated from biological experiments, with appropriate correction 
for multiple comparisons: ****P < 0.0001, ***P < 0.001, **P < 0.01, 
and *P < 0.05. Statistical analysis of DEGs from RNA-seq experi-
ments was performed in CLC Genomics Workbench with FDR or 
Bonferroni correction for multiple comparisons.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/45/eabd3233/DC1
View/request a protocol for this paper from Bio-protocol.
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